چاپ صفحه |  صفحه نخست سامانه |  نویسندگان |  اطلاعات تفضیلی |  دانلود مقاله | دانشگاه علوم پزشکی تبریز |
| نویسنده | نفر چندم مقاله |
|---|---|
| حسن دیانت مقدم | دوم |
| مصطفی خلیلی | اول |
| عنوان | متن |
|---|---|
| خلاصه مقاله | Background: The providing of blood for two categories patients presents a massive problem to blood transfusion organization international. First for patients who need frequent blood transfusions for example thalassaemia or sickle cell disease. That in the result, repeated transfusion, alloimmunization arises owing to incompatibility at minor blood group antigens (Particularly C, E, K, Fya, Fy3, JKb, U, and S). Thus increases the difficulty for finding compatible blood. Second for the individual with the rare phenotype such as Bombay phenotype. Finding: To increases RBCs compatibility for transfusion, transformation A and B to O by glycosidases, antigen masking and silencing using shRNAs has been demonstrated. But they had little success and silencing faced with two problems:1. Partial knockdown antigen genes may be cussing alloantibody formation in vivo, 2. limited proliferative ability of modified HSC and necessity for repetitive shRNA transduction.The CRISPR–Cas9 gene editing technology developed from prokaryotic defense systems, as a flexible method to the prosperous production of in vitro derived RBCs with custom-made blood group. To achieve this goal, researchers using CRISPR developed immortalized HSC cell line that can be Unlimited differentiated to create useful reticulocytes, and as well as using for inactivation of SH2B3 (a negative regulator of cytokine signaling forin vivo expansion of RBCs) boost the maturation and produce of in HSC-derived RBCs. conclusion : Using the built-HSC cell line simultaneously knockouts multiple blood group genes that encode antigens responsible for the most common transfusion incompatibilities to produce a single cell line that could be differentiated to generate RBCs with broad transfusion compatibility. Blood created by genetically modified cells might onetime enable compatible transfusions for patients whom blood matching is challenging |
| کلمات کلیدی | CRISPR–Cas9, gene editing, blood transfusion, RBC compatibility |
| نام فایل | تاریخ درج فایل | اندازه فایل | دانلود |
|---|---|---|---|
| Oral abstarct.pdf | 1398/09/10 | 198458 | دانلود |
| oral-licence.pdf | 1398/09/10 | 568833 | دانلود |
